United States Patent 11,013,809: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
The United States Patent 11,013,809, titled "Sustained delivery formulations of risperidone compound," is a significant patent in the field of pharmaceuticals, particularly in the treatment of psychiatric disorders. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background of the Invention
The patent pertains to a sustained release delivery system for risperidone, a medication commonly used to treat conditions such as schizophrenia, bipolar disorder, and autism spectrum disorder. The invention aims to improve the efficacy and compliance of risperidone treatment by providing a formulation that releases the drug over an extended period[4].
Scope of the Invention
The scope of the invention is defined by its application in treating various psychiatric and neurological disorders. Here are the key aspects:
Diseases Treated
The patent specifies that the sustained release formulations are designed to treat conditions including schizophrenia, bipolar disease, autism spectrum disease, and Gilles de la Tourette syndrome[4].
Formulation Methods
The invention involves various methods for formulating the sustained release system, including the use of polymers, prodrugs, and specific excipients like propylene glycol, acetone, and triethyl citrate. These formulations are designed to ensure a consistent and prolonged release of risperidone[4].
Composition
The composition includes risperidone as the active ingredient, along with various inactive ingredients such as glyceryl triacetate, polyethylene glycol, and propylene carbonate. These components work together to achieve the desired sustained release profile[4].
Claims of the Patent
The claims of the patent are crucial as they define the legal boundaries of the invention. Here are some key claims:
Independent Claims
The patent includes independent claims that describe the overall composition and method of the sustained release formulation. For example, Claim 1 might describe the formulation comprising risperidone and specific excipients designed for sustained release[4].
Dependent Claims
Dependent claims further specify the details of the independent claims, such as the specific ratios of ingredients, the method of preparation, and the expected release profile. These claims help to narrow down the scope and ensure that the invention is distinct from prior art[4].
Patent Landscape
Understanding the patent landscape is essential for assessing the novelty and non-obviousness of the invention.
Prior Art
The patent landscape includes prior art related to sustained release formulations and risperidone delivery systems. The Common Citation Document (CCD) application, for instance, consolidates prior art citations from multiple patent offices, helping to identify relevant prior art[1].
Global Patent Family
The Global Dossier service provided by the USPTO allows users to view the patent family for a specific application, including related applications filed at participating IP Offices. This helps in understanding the global reach and related patents in this field[1].
Competing Patents
Other patents related to sustained release formulations and psychiatric treatments need to be considered. For example, patents related to other antipsychotic medications or different delivery systems could be relevant competitors in the market[1].
Search and Analysis Tools
Several tools are available for searching and analyzing patents, which are crucial for understanding the patent landscape:
Patent Public Search
The USPTO's Patent Public Search tool provides enhanced access to prior art and allows users to search through a vast database of patents and published patent applications[1].
Global Dossier
This service allows users to access the file histories of related applications from participating IP Offices, providing a comprehensive view of the patent family and related citations[1].
Patent Claims Research Dataset
The USPTO's Patent Claims Research Dataset can be used to analyze claims from US patents and published applications, helping to understand trends and measurements of patent scope[3].
Practical Implications
The practical implications of this patent are significant:
Clinical Impact
The sustained release formulation of risperidone can improve patient compliance and reduce the frequency of dosing, which can be particularly beneficial for patients with chronic psychiatric conditions[4].
Market Impact
This patent could influence the market by providing a competitive edge to the patent holder in the field of psychiatric medications. It may also encourage further innovation in sustained release technologies[4].
Key Takeaways
- Innovation in Delivery: The patent introduces a novel sustained release formulation for risperidone, enhancing treatment efficacy and patient compliance.
- Broad Application: The invention is applicable to various psychiatric and neurological disorders.
- Detailed Composition: The patent specifies the use of particular excipients and polymers to achieve the desired release profile.
- Global Relevance: The Global Dossier and other tools highlight the patent's place within the global patent landscape.
- Competitive Edge: The patent provides a competitive advantage in the market for psychiatric medications.
FAQs
Q: What is the primary purpose of the sustained release formulation of risperidone described in US Patent 11,013,809?
A: The primary purpose is to improve the efficacy and compliance of risperidone treatment by providing a formulation that releases the drug over an extended period.
Q: Which conditions are treated by the sustained release formulations described in the patent?
A: The formulations are designed to treat conditions including schizophrenia, bipolar disease, autism spectrum disease, and Gilles de la Tourette syndrome.
Q: What tools can be used to analyze the patent landscape for this invention?
A: Tools such as the USPTO's Patent Public Search, Global Dossier, and the Patent Claims Research Dataset can be used to analyze the patent landscape.
Q: How does the patent impact patient care?
A: The sustained release formulation can improve patient compliance and reduce the frequency of dosing, which is particularly beneficial for patients with chronic psychiatric conditions.
Q: What is the significance of the Global Dossier in relation to this patent?
A: The Global Dossier allows users to view the patent family for a specific application, including related applications filed at participating IP Offices, providing a comprehensive view of the patent's global reach.
Sources
- USPTO - Search for patents: https://www.uspto.gov/patents/search
- U.S. Patent and Trademark Office (USPTO) | USAGov: https://www.usa.gov/agencies/u-s-patent-and-trademark-office
- Patent Claims Research Dataset - USPTO: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
- US11013809B2 - Sustained delivery formulations of risperidone compound - Google Patents: https://patents.google.com/patent/US11013809B2/en
- US-20220354955-A1 - Unified Patents Portal: https://portal.unifiedpatents.com/patents/patent/US-20220354955-A1
